Incyte Corporation $INCY Stock Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in Incyte Corporation (NASDAQ:INCY) by 36.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 975,726 shares of the biopharmaceutical company’s stock after buying an additional 262,372 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.48% of Incyte worth $118,984,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Fiduciary Financial Advisors bought a new stake in Incyte during the 2nd quarter valued at approximately $26,000. Provenance Wealth Advisors LLC purchased a new position in shares of Incyte during the 3rd quarter worth approximately $33,000. Continuum Advisory LLC bought a new position in shares of Incyte in the 2nd quarter worth approximately $36,000. Latitude Advisors LLC bought a new position in shares of Incyte in the 3rd quarter worth approximately $39,000. Finally, Quantbot Technologies LP bought a new position in shares of Incyte in the 2nd quarter worth approximately $52,000. 96.97% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Pablo J. Cagnoni sold 10,801 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the sale, the insider directly owned 183,200 shares in the company, valued at $23,002,592. This trade represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total transaction of $72,565.60. Following the transaction, the insider owned 21,126 shares in the company, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 14,053 shares of company stock valued at $1,726,519. 16.20% of the stock is currently owned by corporate insiders.

Incyte Price Performance

Shares of INCY stock opened at $119.65 on Monday. The company has a 50 day moving average price of $119.62 and a 200-day moving average price of $108.51. Incyte Corporation has a 52 week low of $89.25 and a 52 week high of $132.60. The firm has a market capitalization of $24.39 billion, a PE ratio of 63.64, a P/E/G ratio of 4.36 and a beta of 0.78.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. The firm had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period last year, the business posted $2.26 EPS. Analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. TD Cowen upped their price target on Incyte from $138.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, October 21st. Wells Fargo & Company lowered their price objective on Incyte from $128.00 to $127.00 and set an “equal weight” rating for the company in a research report on Friday, October 30th. Canaccord Genuity Group started coverage on Incyte in a research report on Thursday, August 20th. They set a “buy” rating and a $152.00 price objective for the company. Oppenheimer set a $152.00 target price on shares of Incyte in a report on Tuesday, October 27th. Finally, Piper Sandler upped their target price on shares of Incyte from $110.00 to $130.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Eleven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $132.86.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Incyte Profile

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.